Free Trial
LON:GNS

Genus (GNS) Share Price, News & Analysis

Genus logo
GBX 1,996 -49.00 (-2.40%)
As of 10:23 AM Eastern

About Genus Stock (LON:GNS)

Key Stats

Today's Range
1,980
2,085
50-Day Range
1,585.52
2,129.37
52-Week Range
1,424
2,160
Volume
70,510 shs
Average Volume
245,740 shs
Market Capitalization
£1.31 billion
P/E Ratio
165.45
Dividend Yield
1.60%
Price Target
GBX 2,150
Consensus Rating
Buy

Company Overview

Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers technical services to farmers. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.

Genus Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
7th Percentile Overall Score

GNS MarketRank™: 

Genus scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Genus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Genus has only been the subject of 1 research reports in the past 90 days.

  • Read more about Genus' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Genus is 166.40, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.81.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Genus is 166.40, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.42.

  • Price to Earnings Growth Ratio

    Genus has a PEG Ratio of 2.87. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Genus has a P/B Ratio of 2.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for GNS.
  • Dividend Yield

    Genus pays a meaningful dividend of 1.69%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Genus does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Genus is 265.25%. Payout ratios above 75% are not desirable because they may not be sustainable.

  • Read more about Genus' dividend.
  • Short Interest

    There is no current short interest data available for GNS.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Genus this week, compared to 1 article on an average week.
  • Search Interest

    14 people have searched for GNS on MarketBeat in the last 30 days. This is an increase of 180% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Genus insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.75% of the stock of Genus is held by insiders.

  • Percentage Held by Institutions

    77.79% of the stock of Genus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Genus' insider trading history.
Receive GNS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genus and its competitors with MarketBeat's FREE daily newsletter.

GNS Stock News Headlines

Genus Stock Price History
"I'm risking my reputation on this"
Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.
Kepler Capital Keeps Their Buy Rating on Genus plc (GNS)
See More Headlines

GNS Stock Analysis - Frequently Asked Questions

Genus' stock was trading at GBX 1,550 at the beginning of 2025. Since then, GNS shares have increased by 29.5% and is now trading at GBX 2,007.50.
View the best growth stocks for 2025 here
.

Genus plc (LON:GNS) announced its earnings results on Thursday, February, 27th. The company reported $39.80 EPS for the quarter. Genus had a trailing twelve-month return on equity of 1.41% and a net margin of 1.18%.
Read the conference call transcript
.

Shares of GNS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Genus investors own include Meta Platforms (META), Lloyds Banking Group (LLOY), Rolls-Royce Holdings plc (RR.L), AstraZeneca (AZN), Barclays (BARC), BP (BP) and Clinigen Group (CLIN).

Company Calendar

Last Earnings
2/27/2025
Today
7/01/2025

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Biotechnology
Sub-Industry
Personal Services
Current Symbol
LON:GNS
CIK
N/A
Fax
N/A
Employees
480
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
GBX 2,150
High Stock Price Target
GBX 2,150
Low Stock Price Target
GBX 2,150
Potential Upside/Downside
+7.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
166.27
Forward P/E Ratio
28.27
P/E Growth
2.87
Net Income
£7.87 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£666.67 million
Cash Flow
GBX 39.67 per share
Price / Cash Flow
50.56
Book Value
GBX 827.95 per share
Price / Book
2.42

Miscellaneous

Free Float
N/A
Market Cap
£1.31 billion
Optionable
Not Optionable
Beta
0.37
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (LON:GNS) was last updated on 7/1/2025 by MarketBeat.com Staff
From Our Partners